A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2 negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date25/03/21 → 31/12/24

Keywords

  • Adenocarcinoma
  • Gastric cancer
  • Clinical trial